1. Introduction {#s0005}
===============

Blood-oxygen level dependent (BOLD) MRI is a simple and effective approach for non-invasively imaging dynamic changes in cerebral blood flow (CBF) at high temporal resolution. Since its introduction, BOLD has become a standardized clinical sequence that has enabled the investigation of brain function and physiology in health and disease. One recent and notable application of BOLD imaging is the quantification of cerebrovascular reactivity (CVR), which characterizes the physiological capacity of the cerebral vasculature to modulate blood flow and can be used to assess vascular dysfunction in the brain ([@bb0135]). As such, CVR is a clinically relevant parameter that is closely associated with cerebral autoregulatory function ([@bb0125]).

CVR measures can be acquired by administering a vasoactive stimulus, such as carbon dioxide (CO~2~) gas, to the subject during a BOLD scan. By performing a linear temporal correlation between the BOLD signal time-course and partial pressures of CO~2~ (PCO~2~) traces sampled from the subject, detailed CVR maps of the brain can be generated. Previous studies combining BOLD imaging and a CO~2~ stimulus have demonstrated that these maps can identify regional and global deficits in CBF regulation across a wide range of disorders, including traumatic brain injury, intracranial stenosis, moyamoya, and sickle cell disease ([@bb0090], [@bb0100], [@bb0095], [@bb0035], [@bb0010], [@bb0040], [@bb0070], [@bb0075]). In addition, the use of novel computer-controlled gas sequencers has enabled rapid and accurate targeting of PCO~2~ levels ([@bb0130]), resulting in highly reproducible CVR results in both adults and children ([@bb0065], [@bb0085]). However, recent investigations into the temporal dynamics of the BOLD response to a CO~2~ stimulus have highlighted potential limitations to our understanding and interpretation of CVR ([@bb0045]).

Conventional CVR analysis methods are designed to be sensitive to magnitude differences in the BOLD response, but assume that its temporal dynamic properties are consistent across the entire brain. However, changes in blood gases may affect the grey matter (GM) before reaching the white matter (WM) tissue as a consequence of their relative vascular hierarchy ([@bb0145]). In addition, regionally specific CBF response delays have been noted between different populations (e.g. native-born high altitude versus native sea level residents ([@bb0160])) and reductions in CVR have been shown to correlate with longer regional arterial transit times ([@bb0120]). Such temporal discrepancies are not accounted for in conventional CVR analysis. Another important consideration is the rate at which the vasculature can alter blood flow. The dynamic response to a stimulus requires a transient period of vasodilation or constriction before CBF reaches steady state ([@bb0045]). In a study on patients with steno-occlusive disease, the rate of BOLD signal increase in response to CO~2~ step change was modeled with an exponential function, demonstrating significantly slower rise times in the affected hemisphere compared to healthy tissue ([@bb0115]). The combination of these temporal factors can lead to CVR maps exhibiting artificially reduced CO~2~ reactivity because conventional CVR is calculated as a linear temporal correlation without correcting for delayed responses and slowed dynamics in different tissues.

Delayed and slowed vascular dynamics may have significant implications for the assessment of CVR in pathologies such as sickle cell disease (SCD). SCD is a genetic disorder affecting the oxygen carrying red blood cells in the body, resulting in abnormal blood flow and vascular complications ([@bb0140]). In children, SCD is associated with an increased risk of silent infarction and overt ischemic stroke due to the combination of severe anemia, vasculopathy, and endothelial dysfunction ([@bb0140], [@bb0110]). CVR has been shown to be reduced in this population ([@bb0070], [@bb0075]), suggesting that the inability of the vasculature to dilate may be a primary factor leading to ischemic damage in the brain ([@bb0155]). However, the physiological mechanisms behind this impairment has not been fully explored and it is currently unknown whether low CVR in SCD is truly representative of exhausted vasodilatory capacity caused by chronic hyperaemia, or a result of delayed and/or slower hemodynamic responses in the brain.

To investigate the temporal characteristics of BOLD CVR measures obtained in children with SCD, transfer function analysis (TFA) can be used. TFA is a technique that has previously been applied to the correlation of cerebral autoregulation measures such as arterial blood pressure and blood flow velocity ([@bb0170], [@bb0150], [@bb0015]). Instead of computing CVR using a linear temporal correlation, the BOLD and CO~2~ data time-series are analyzed in the frequency domain. As a result, the magnitude (Gain) of a response to a stimulus is calculated independently of any temporal offset (Phase) between the measured waveforms. [@bb0030] proposed the application of TFA to BOLD CVR data to demonstrate that conventional methods generally underestimated CO~2~ reactivity as regions of slow response are erroneously characterized as low or negative reactivity. Hence, the quantification of the magnitude response as well as identification of regions of significantly delayed or slowed responses may provide additional insights into the function of cerebral vessels that are not evident in conventional CVR measures alone. However, current published data is limited to a small sample of healthy controls and patients with severe regional vasculopathy (Moyamoya) ([@bb0030]), and quantitative group comparisons remain unfeasible due to the insufficient subject numbers and inherent heterogeneity of the impairment under investigation.

The purpose of this study was therefore to investigate the application of TFA in a population with known systemic cerebrovascular compromise, namely children with SCD ([@bb0070], [@bb0075]), and compare these measures to those of healthy controls. We hypothesize that the separation of magnitude and phase contributions using TFA will correct any potential underestimation of CVR in both patients and healthy controls. In addition, the extent to which CVR is corrected using TFA will correlate with the corresponding Phase calculated by TFA. We also hypothesize that TFA will have a greater effect on patient data compared to controls, suggesting that the cerebral blood vessels in children with SCD are slower to respond to a CO~2~ stimulus.

2. Materials and methods {#s0010}
========================

2.1. Subjects and ethical approval {#s0015}
----------------------------------

This is a retrospective study of CVR and structural MRI data acquired from 62 pediatric SCD patients (age 10 to 18 years) and 34 age matched controls. The SCD group consisted of patients with HbSS or HbSβ^0^ and had no history of overt stroke or other neurological impairments. The procedures in the described study conform to The Code of Ethics of the World Medical Association (Declaration of Helsinki) and were approved by the Research Ethics Board of The Hospital for Sick Children. All patients and healthy controls provided informed written consent prior to participating in the study.

2.2. Experimental protocol {#s0020}
--------------------------

CO~2~ stimulus: Prior to imaging, subjects were fitted with a breathing mask connected to a computer-controlled gas sequencer (RespirAct, Thornhill Research Inc., Toronto, Canada) ([@bb0130]). The gas sequencer precisely controls the flow and concentration of oxygen (O~2~) and CO~2~ gas delivered to the mask while simultaneously sampling the exhaled end-tidal partial pressures of O~2~ (P[et]{.smallcaps}O~2~) and CO~2~ (P[et]{.smallcaps}CO~2~). Measurements of P[et]{.smallcaps}CO~2~ have been shown to be an effective surrogate for quantifying a hypercapnic stimulus as it closely correlates to arterial blood gas levels ([@bb0050]). The subjects wear the mask while in the MRI during the CVR measurement, in which the sequencer alternates between 60 s of targeted normocapnia (P[et]{.smallcaps}CO~2~ = 40 mmHg) and 45 s of targeted hypercapnia (P[et]{.smallcaps}CO~2~ = 45 mmHg) for a total of 8 min, as illustrated in [Fig. 1](#f0005){ref-type="fig"}a. P[et]{.smallcaps}O~2~ was maintained at 100 mmHg for the duration of the CVR measurement. The mean P[et]{.smallcaps}CO~2~ in normocapnia for all subjects was 39.9 ± 1.1 mmHg and in hypercapnia was 44.4 ± 1.2 mmHg. Mean P[et]{.smallcaps}O~2~ was measured at 104.6 ± 4.0 mmHg in normocapnia and 106.1 ± 4.2 mmHg in hypercapnia.

### 2.2.1. MRI protocol {#s0025}

Imaging for the study was performed on a 3 Tesla clinical MRI (MAGNETOM Tim Trio, Siemens Healthcare, Erlangen, Germany) with a 32-channel phased array head coil. CVR data were acquired using a BOLD scan that was run in synchrony with the aforementioned CO~2~ stimulus ([Fig. 1](#f0005){ref-type="fig"}b). The BOLD pulse sequence was a single-shot gradient-echo EPI with the following parameters: TR = 2000 ms, TE = 30 ms, FOV = 220 × 220 mm, matrix = 64 × 64, slices = 25, slice thickness = 4.5 mm, flip angle = 90°, volumes = 240, time = 8:04 min. In addition, a 3D T1-weighted anatomical image was acquired for co-registration and tissue classification: TR = 2300 ms, TE = 2.96 ms, FOV = 256 × 240 × 192 mm, voxel = 1.0 mm^3^ isotropic, flip angle = 9°, GRAPPA = 2, time = 5:03 min.

### 2.2.2. Data analysis {#s0030}

MRI data and sampled P[et]{.smallcaps}CO~2~ waveforms were transferred to an independent workstation for post-processing and TFA. The BOLD data series were first corrected for motion using MCFLIRT ([@bb0060]). TFA was performed by computing the voxel-wise frequency response function between the principal harmonic of the BOLD data and its corresponding P[et]{.smallcaps}CO~2~ time series, as previously described by [@bb0030]. The resulting maps, which were generated by selecting a frequency of 0.01 Hz to reflect the temporal period (1/frequency) of the CO~2~ stimulus paradigm, consists of an absolute magnitude (Gain) and a complex argument (Phase) calculated for each voxel. The Gain based measure of CVR (CVR~Gain~) represents the magnitude of the power transfer between the stimulus and the response at 0.01 Hz, and the Phase represents a combined measure of the delay and dynamics of the response relative to the stimulus reference point. The reference at which the delay between the stimulus and response equals zero was manually chosen by aligning the mean BOLD signal across the entire brain with the P[et]{.smallcaps}CO~2~ waveform. The CVR~Gain~ and Phase maps generated for each subject were co-registered to the T1-weighted anatomical images using FSL-FLIRT ([@bb0055]). Next, GM and WM masks of each subject were computed from the T1-weighted anatomical data using FSL-FAST ([@bb0165]) to calculate regional averages.

Conventional CVR (CVR~Conv~) maps computed from a linear temporal correlation were also created for comparison. The BOLD and P[et]{.smallcaps}CO~2~ data were temporally aligned as before, and each voxel value was defined by the linear regression slope: CVR~Conv~ = %ΔBOLD/ΔP[et]{.smallcaps}CO~2~, where %ΔBOLD is the relative change in BOLD signal and ΔP[et]{.smallcaps}CO~2~ is the change in end-tidal CO~2~. These maps were co-registered to the T1-weighted data and averaged over GM and WM regions, in the same manner as the CVR~Gain~ and Phase maps.

To compare differences between SCD patients and healthy controls, a Student\'s *t*-test was performed on the GM and WM phase between the two groups. In addition, the change in value between mean CVR~Conv~ and CVR~Gain~ in GM and WM was calculated and compared between groups to illustrate how TFA results compensate for regional temporal delays. Differences in change were computed using a z-test ([@bb0020]). The role of Phase in the TFA correction of CVR estimates was further investigated by performing a linear regression analysis between the relative change in calculated CVR and the Phase delay computed by TFA. A *p*-value of less than 0.05 was considered statistically significant.

3. Results {#s0035}
==========

All data were successfully analyzed with the TFA method and visual inspection of the maps did not reveal any anomalous results to be excluded (e.g. abnormally high or low values). The mean age at the date of MRI scanning was 14.6 ± 2.6 years for the SCD group (30 males, 32 females) and 15.0 ± 4.7 years for controls (17 males, 17 females). Haematology results from the patients\' most recent clinic visit showed a mean haematocrit of 0.275 ± 0.041, which is significantly lower than the expected values in healthy controls ([@bb0025]). The average time interval between the blood sample analysis and imaging was 32.7 ± 45.2 days, with 3 patients whose clinic visit and MRI were greater than 160 days apart. The average interval is 24.3 ± 23.4 days if the 3 outliers are removed. Representative slices from the CVR~Conv~, CVR~Gain~, and Phase maps of an example SCD patient and an example healthy control are provided in [Fig. 2](#f0010){ref-type="fig"}. The figure shows qualitatively that CVR~Gain~ maps have overall higher values for both subjects.

A quantitative summary of group results comparing CVR~Conv~ to CVR~Gain~ are provided in [Table 1](#t0005){ref-type="table"}. In both SCD and control groups, the difference between Gain and CVR is significant in GM and WM. However, by examining the ratio between WM and GM, it becomes evident that TFA has a significantly greater effect on SCD patients compared to controls. The increase is particularly more pronounced in the WM of SCD, which is also subtly visible in the CVR maps in [Fig. 2](#f0010){ref-type="fig"}. This observation corresponds to the representative Phase maps displaying larger regions of high temporal lag in patient WM compared to controls. [Table 2](#t0010){ref-type="table"} compares mean Phase values between groups. The GM is the dominant source of signal and, hence, is used as the reference for phase alignment. As such, Phase values in the GM for both groups are very similar and only the relative temporal lag in the WM Phase can be observed. Taking the average relative difference between WM and GM Phase, a greater distinction between patient and control groups exists but the results were not statistically significant, which is unexpected as Phase was predicted to be closely associated with the change in CVR caused by applying TFA. A possible explanation for this discrepancy is that phase change is calculated as a difference, while magnitude change is calculated as a ratio. This effect is shown in [Fig. 3](#f0015){ref-type="fig"}, where the relation between WM to GM Phase difference (ΔPhase) and the CVR~Gain~/CVR~Conv~ ratio is plotted. There appears to be a logarithmic pattern in the patient data, resulting in a subset of points where a minor increase in ΔPhase is met by a significant increase in CVR ratio. In the control data, the range of ΔPhase remains confined in the 'linear' range and the logarithmic pattern is not observed.

[Fig. 4](#f0020){ref-type="fig"} plots the CVR~Conv~ versus CVR~Gain~ in both patients and controls. A linear least squares fit has been overlaid to illustrate the different effect of TFA on the two groups. In both GM and WM, the fit for the patient data has a significantly steeper slope than for controls, suggesting that CVR estimates in SCD patients are more strongly affected by the TFA processing method. These results are outlined in [Table 3](#t0015){ref-type="table"}.

The influence of Phase on the underestimation of CVR is illustrated in [Fig. 5](#f0025){ref-type="fig"}. A strong linear correlation is observed between the increase in mean CVR using the TFA method and the corresponding measured Phase lag in both the GM (*r* = 0.72, *p* = 1.2 × 10^− 16^) and WM (*r* = 0.55, *p* = 6.2 × 10^− 9^). There is no statistically significant difference in slope between the patient and the control group or between GM and WM (*p* \> 0.2).

4. Discussion {#s0040}
=============

The present study demonstrates the application of the TFA method in pediatric patients with SCD, a population with systemic cerebrovascular impairment. This method is an extension of conventional CVR calculations as it accounts for and quantifies the temporal dynamic component of the CBF response to a hypercapnic stimulus across different tissue regions. Using data acquired from BOLD MRI in combination with a CO~2~ step stimulus, we report group results of TFA in children with SCD and healthy controls, and contrast them to conventional CVR maps.

In our cohort of pediatric subjects, we observed that patients with SCD have significantly lower CVR than healthy controls, which is in agreement with previous literature in children and adults ([@bb0070], [@bb0075], [@bb0105]). The most noticeable difference after application of TFA is that the CVR~Gain~ values are higher than CVR~Conv~ in both the patient and control groups. This finding occurs because CVR~Gain~ values are insensitive to potential temporal misalignment of the BOLD and CO~2~ waveforms, and regional differences in the speed of response ([@bb0030]). In addition, focusing the analysis on a single harmonic frequency (0.01 Hz) removes spurious higher frequency signal fluctuations. CVR~Gain~ therefore serves as a more accurate representation of the vessels\' capacity to increase or decrease CBF. Meanwhile, the temporal dynamic aspect of the CBF response is represented by Phase. As [Fig. 2](#f0010){ref-type="fig"} illustrates, the region of greater Phase lag (dark colours) is more prevalent in the WM of the SCD subject compared to the control. This phase difference coincides with a further reduction in WM CVR~Conv~ relative to CVR~Gain~. As outlined in [Table 1](#t0005){ref-type="table"}, the ratio of WM/GM CVR~Gain~ is significantly higher than the CVR~Conv~ ratio in the patient group (*p* = 0.007), while the corresponding ratios in controls are relatively unchanged (*p* = 0.469).

The differences in CVR ratios suggest that the transient BOLD response in the WM of SCD is significantly slower compared to that in controls, which is exemplified in [Fig. 2](#f0010){ref-type="fig"}b. While we observed that the mean Phase lag between GM and WM in the SCD group is also greater than in controls, the difference between the two groups was only approaching statistical significance (*p* = 0.107). This may be because the calculation of the WM to GM CVR ratio results in a non-linear relation that is not reproduced when computing the WM to GM Phase difference, as illustrated in [Fig. 3](#f0015){ref-type="fig"}. As a result, a significant difference between measures of CVR ratios may not necessarily translate to a significant difference in Phase change. However, as demonstrated in [Fig. 5](#f0025){ref-type="fig"}, which examines GM and WM data separately, the calculated Phase is directly correlated to amount by which the TFA corrects the underestimation of CVR. Therefore, the Phase information in combination with the CVR~Gain~ maps from TFA does provide a more robust and accurate understanding of CVR impairment in SCD.

In [Table 2](#t0010){ref-type="table"}, the lack of Phase difference between groups in the GM is a consequence of the methodology used to set the reference. The reference is individually determined for each subject by temporally shifting the data to maximize the coherence between BOLD and CO~2~ signals. An alternative approach would be to align the BOLD and CO~2~ signal transitions to determine the Phase reference, similar to the normocapnia-hypercapnia boundaries indicated in [Fig. 1](#f0005){ref-type="fig"}b. By doing so, a statistically significant Phase difference between SCD patients and healthy controls may potentially be revealed in both GM and WM. However, this strategy would involve visually matching the waveforms, which is subjective and introduces operator dependent bias. Therefore, the more systematic approach of utilizing coherence was chosen for our analysis.

Our results also highlight how CVR~Gain~ maps compare to CVR~Conv~ across different subject groups. As plotted in [Fig. 4](#f0020){ref-type="fig"}, the TFA approach has a greater effect on CVR estimates (greater slope) in SCD patients compared to healthy controls in both GM and WM. This is an important finding as it demonstrates that the temporal dynamics of the BOLD response is slower in SCD and is partially responsible for the reduction in measured CVR~Conv~. From a clinical perspective, it becomes necessary to investigate whether CVR~Gain~ alone is a reliable predictor of ischemic injury in SCD, or if the Phase lag also represents a significant component of the impaired cerebrovascular reserve which could lead to tissue ischemia.

The limitations of conventional CVR analysis have been known for many years and various other techniques have also been employed to account for the temporal characteristics of the BOLD response. [@bb0005] proposed a sinusoidal stimulus paradigm so that the calculation of CVR will default to a single frequency analysis. While this approach removes the transient phase of the BOLD response, it necessitates the use of sophisticated equipment to control the stimulus, which may not be feasible in most clinical settings. Moreover, the quantification of transient period in response to a step function stimulus may be of clinical value. More recently, [@bb0115] introduced the concept of parsing the BOLD data into a steady state and a dynamic regime. This enabled the fitting of the transient rise and fall of the BOLD signal within the dynamic regime into a hemodynamic response function characterized by an exponential function with a time constant Tau. However, the use of a single exponential function to model the BOLD response to a stimulus has not yet been validated. We chose to implement TFA in our study for its simplicity and robust nature, and because it is a concept that is already well recognized in the analysis of cerebral hemodynamics ([@bb0170]).

The primary issue with CVR imaging in a population such as sickle cell disease is that the BOLD signal does not directly measure blood flow change and may be confounded by low haematocrit (or Hb) levels. However, an fMRI study by [@bb0175] showed the BOLD signal was not correlated to Hb concentration in children with SCD. They proposed that any reduction in the BOLD response due to low Hb is met by a corresponding increase in CBV, that balances the net total Hb count in a given voxel. A separate study using positron emission tomography in adults with chronic renal failure, CO~2~ reactivity measurements were shown to be significantly correlated to haematocrit ([@bb0080]). Their findings suggest that reductions in BOLD-CVR are primarily driven by physiological impairment irrespective of Hb concentration.

One fundamental aspect of this experiment that deviates from the original CVR TFA study is the CO~2~ stimulus paradigm. In designing a CVR protocol for children, the target P[et]{.smallcaps}CO~2~ during hypercapnia step was programmed to 45 mmHg, which is considerably lower than the 50 mmHg described by [@bb0030] The cycles of hypercapnia were also shorter (45 s) as younger subjects are less tolerant to prolonged periods of increased CO~2~. Despite these differences, we were able to generate clear maps of Phase differences that correspond well to anatomical features of the brain. This suggests that a smaller CO~2~ increase and reduced exposure to hypercapnia can still produce reasonable data for TFA. However, the potential errors that may accumulate from such changes cannot be estimated without a direct comparison between the two stimuli. We note that the results presented in this study are based on whole-brain GM and WM averages to demonstrate differences between groups, and that subsequent research may focus on more detailed examinations of the brain to determine specific regional properties of sickle cell and other cerebrovascular diseases.

Future studies may also consider TFA across multiple harmonics. The choice to focus the analysis on a single frequency (0.01 Hz) was based on the period of our CO~2~ stimulus paradigm (\~ 100 s). Higher order harmonics were discarded in order to remove noise and simplify the interpretation of the CVR data. However, there may be valuable information in these other frequencies that have yet to be investigated but such endeavours are beyond the scope of this study. Additional research outlining the applications of multiple frequency analysis is needed before it can be reliably implemented in clinical studies.

In conclusion, we present the first group analysis data showcasing how CVR results differ between TFA and conventional analysis techniques in children with SCD compared to healthy controls. The CVR~Gain~ and Phase values computed from TFA represent the two components that comprise CVR~Conv~. As such, they can reveal clinically relevant information that CVR~Conv~ alone does not provide. These aspects should be considered in future studies and analyses involving CVR in subjects with SCD as well as other cerebrovascular diseases.
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![a) The targeted end-tidal values of the CVR protocol shown in grey, and the corresponding sampled P[et]{.smallcaps}CO~2~ and P[et]{.smallcaps}O~2~ waveforms for a single subject are overlaid in red and blue, respectively. b) Examples of the BOLD response to CO~2~ step change for an SCD patient and a healthy control subject. The BOLD signal was averaged over the entire grey matter (black line) and white matter (grey line) and plotted over time. A low pass filter was performed on the data to reduce signal fluctuations due to background and physiological noise. The blue shaded region represents the periods of normocapnia, and the orange shaded region indicates the administration of the hypercapnic stimulus. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)](gr1){#f0005}

![Representative slices from a CVR~Conv~, CVR~Gain~, and Phase map for a) a 11 year old female with SCD and b) a healthy 12 year old female control subject.](gr2){#f0010}

![Scatter plot showing the non-linear relation when comparing the difference between WM and GM. ΔPhase is calculated as the mean Phase difference between the WM and GM of each subject. The GM/WM ratio of the CVR increase due to TFA (CVR~Gain~/CVR~Conv~) is plotted along the x-axis.](gr3){#f0015}

![Plot of mean CVR~Gain~ versus CVR~Conv~ in the a) GM and b) WM. Subject data points are identified as either Patients (■) or Controls (◊). Linear trend lines have been added in black to show differences in slope between the Patient and Control group.](gr4){#f0020}

![Scatter plots demonstrating the relation between Phase and the CVR~Gain~/CVR~Conv~ ratio in the a) GM and b) WM. Subject data points are identified as either Patients (■) or Controls (◊). In both plots, the effect of TFA on CVR estimates is linearly correlated with the Phase lag detected by TFA.](gr5){#f0025}

###### 

Comparison of CVR~Conv~ and CVR~Gain~ in grey matter (GM) and white matter (WM) within SCD and Control groups. The ratio of CVR between WM and GM is also included to show that transfer function analysis has a significantly greater effect in the WM than GM for SCD patients. Values expressed as mean CVR ± standard deviation in units of %ΔBOLD/mmHg.

Table 1

          SCD patients    Healthy controls                                                     
  ------- --------------- ------------------ ----------------- --------------- --------------- ----------------
  GM      0.098 ± 0.034   0.142 ± 0.054      4.48 × 10^− 7^    0.188 ± 0.052   0.263 ± 0.049   6.54 × 10^− 8^
  WM      0.068 ± 0.023   0.106 ± 0.033      1.40 × 10^− 11^   0.116 ± 0.029   0.162 ± 0.028   7.08 × 10^− 9^
  WM/GM   0.705 ± 0.122   0.796 ± 0.237      7.21 × 10^− 3^    0.659 ± 0.083   0.653 ± 0.085   0.469

###### 

Comparison of average Phase in WM and GM between SCD patients and healthy controls. Negative Phase indicates that the BOLD signal lags behind the CO~2~ waveform. Values are expressed as mean Phase ± standard deviation in units of radians.

Table 2

  Phase     SCD patients      Healthy controls   *p*-Value
  --------- ----------------- ------------------ -----------
  GM        − 0.387 ± 0.142   − 0.390 ± 0.121    0.907
  WM        − 0.525 ± 0.173   − 0.485 ± 0.139    0.248
  WM - GM   − 0.138 ± 0.137   − 0.095 ± 0.101    0.107

###### 

Linear fit parameters (slope ± standard deviation) of CVR~Gain~ versus CVR~Conv~. The *p*-values indicating the significance of each correlation as well as the difference between slopes are provided.

Table 3

       SCD patients    Healthy controls   Change in slope                    
  ---- --------------- ------------------ ----------------- ---------------- ----------------
  GM   1.314 ± 0.103   4.31 × 10^− 19^    0.748 ± 0.108     7.40 × 10^− 8^   1.38 × 10^− 4^
  WM   1.173 ± 0.103   1.25 × 10^− 16^    0.707 ± 0.116     8.09 × 10^− 7^   3.46 × 10^− 3^
